Skip to main content
Premium Trial:

Request an Annual Quote

ActiveSight, Thermo Electron

Premium
ActiveSight lauched this week its inducible nitric oxide synthase, oriNOS, and peroxisome proliferators-activated recptor gamma, or PPAR gamma, “ready to go” protein crystals for drug discovery. The company now has 14 proteins in its portfolio.
 
iNOS  produces large bursts of nitric oxide as part of the immune response. Overproduction of it has been linked to inflammation and autoimmune diseases, ActiveSight said.
 
PPAR is the target of the glitazone family of drugs and in addition to being a diabetes target, may also play a role in cancer and inflammation. 
 

 
Thermo Electron has updated its Darwin LIMS for pharmaceutical manufacturing R&D and QA-QC. Darwin 1.1 now features extensive interfacing capabilities, providing tight integration with SAP, and historical data trending and charting functionality.
 
“The embedded charting and trending for product stability testing allows for real- time data review and rapid reporting,” the company said in a statement. Darwin 1.1 is also optimized now to operate on the Oracle 10g platform.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.